SEC Form 4 · accession 0000899243-16-023885
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric D. Shaff
Officer — CFO and EVP
Period of report
Jun 27, 2016
Accepted (ET)
Jun 29, 2016 · 7:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 27, 2016 | M | 3,334 | $7.79 | A | 3,334 | D | |
| Common Stock | Jun 27, 2016 | S | 3,334 | $28.00 | D | 0 | D | |
| Common Stock | Jun 28, 2016 | M | 1,667 | $7.79 | A | 1,667 | D | |
| Common Stock | Jun 28, 2016 | S | 1,667 | $28.85 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $7.79 | Jun 27, 2016 | M | 3,334 | D | — | Dec 8, 2024 | Common Stock | 3,334 | 239,654 | D |
| Stock Option (right to buy)F2 | $7.79 | Jun 28, 2016 | M | 1,667 | D | — | Dec 8, 2024 | Common Stock | 1,667 | 237,987 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted on February 26, 2016 by the Reporting Person.
- F2The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.